Apotex NZ Ltd - search results

New Zealand - English - Medsafe (Medicines Safety Authority)

apo-prazosin

apotex nz ltd - prazosin hydrochloride 5.5mg equivalent to 5 mg prazosin; - tablet - 5 mg - active: prazosin hydrochloride 5.5mg equivalent to 5 mg prazosin excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose polysorbate 80 - hypertension: prazosin is effective in the management of primary hypertension, and also secondary hypertension from various causes. prazosin may be used as the sole agent, but it is generally more effective if used in combination with a diuretic. prazosin can be used successfully with other antihypertensive agents. prazosin may be used safely by hypertensive patients with impaired renal function. congestive cardiac failure: prazosin may be added to the therapeutic regime of patients who have become refactory to conventional therapy with cardiac glycosides and diuretics. raynaud's phenomenon and raynaud's disease benign prostatic hyperplasia: an adjunct in the symptomatic treatment of urinary obstruction caused by bph in patients waiting for prostatic surgery

New Zealand - English - Medsafe (Medicines Safety Authority)

apo-oxybutynin

apotex nz ltd - oxybutynin hydrochloride 1 mg/ml; - syrup - 1 mg/ml - active: oxybutynin hydrochloride 1 mg/ml excipient: berry flavour (mix) 538632 citric acid monohydrate fast green fcf glycerol methyl hydroxybenzoate purified water sodium citrate dihydrate sorbitol as 70% solution, 366 mg/ml sucrose - oxybutynin chloride is indicated in adults and children over 5 years of age for the management of urgency and incontinence that characterise neurogenic bladder disorders and idiopathic destrusor instability.

New Zealand - English - Medsafe (Medicines Safety Authority)

apo-amlodipine

apotex nz ltd - amlodipine besilate 14mg equivalent to to 10 mg amlodipine; - tablet - 10 mg - active: amlodipine besilate 14mg equivalent to to 10 mg amlodipine excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - apo-amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor. apo-amlodipine is indicated for the first line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (prinzmetal's or variant angina) of coronary vasculature. amlodipine may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. apo-amlodipine may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta blockers.

New Zealand - English - Medsafe (Medicines Safety Authority)

apo-amlodipine

apotex nz ltd - amlodipine besilate 3.5mg equivalent to 2.5 mg amlodipine; - tablet - 2.5 mg - active: amlodipine besilate 3.5mg equivalent to 2.5 mg amlodipine excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - apo-amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor. apo-amlodipine is indicated for the first line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (prinzmetal's or variant angina) of coronary vasculature. amlodipine may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. apo-amlodipine may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta blockers.

New Zealand - English - Medsafe (Medicines Safety Authority)

apo-amlodipine

apotex nz ltd - amlodipine besilate 7mg equivalent to to 5 mg amlodipine; - tablet - 5 mg - active: amlodipine besilate 7mg equivalent to to 5 mg amlodipine excipient: lactose monohydrate magnesium stearate maize starch microcrystalline cellulose - apo-amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme inhibitor. apo-amlodipine is indicated for the first line treatment of myocardial ischaemia, whether due to fixed obstruction (stable angina) and/or vasospasm/vasoconstriction (prinzmetal's or variant angina) of coronary vasculature. amlodipine may be used where the clinical presentation suggests a possible vasospastic/vasoconstrictive component but where vasospasm/vasoconstriction has not been confirmed. apo-amlodipine may be used alone as monotherapy, or in combination with other antianginal drugs in patients with angina that is refractory to nitrates and/or beta blockers.